BACKGROUND AND AIMSThe evidence on the cumulative participation and yield in multiple rounds of colorectal cancer (CRC) screening based on fecal immunochemical test is sparse. We aimed to assess the trends in participation and detection for advanced colorectal neoplasm under different screening intervals in multi-round FIT-based CRC screening by synthesizing the current available evidence.METHODSPubMed, Embase, and Cochrane were retrieved from January 1, 2002 to April 16, 2024 for potential eligible studies and then we synthesized participation and advanced colorectal neoplasm detection rates for each screening round, along with their respective 95% confidence intervals.RESULTS19 studies involving a total of 2,296,071 individuals were included. As screening rounds increased, participation exhibited a gradual consistent increase, reaching 78.45% and 74.97% for annual and biennial screening strategies. For annual screening, the cumulative detection rates for 3 rounds were 1.38% (95% CI: 1.18-1.63%), 1.95% (95% CI: 1.72-2.21%), and 2.50% (95% CI: 2.29-2.72%), respectively. For biennial screening, the cumulative detection rates for 4 rounds were 2.22% (95% CI: 1.22-3.22%), 3.44% (95% CI: 2.06-4.82%), 4.26% (95% CI: 2.70-5.83%), and 5.10% (95% CI: 3.28-7.29%), respectively. Notably, the per-round detection rate of advanced colorectal neoplasms declined yet as the screening progressed.CONCLUSIONIn population-based CRC screening programs, the participation exhibited a slow upward trend for both screening strategies, but the incremental benefits in CRC detection gradually diminished. Tailored strategies, such as extending intervals for individuals with multiple negative FIT results, might optimize effectiveness and cost-efficiency in population-based CRC screening.
{"title":"Participation and Yield in Multiple Rounds of Colorectal Cancer Screening based on Fecal Immunochemical Test: A Systematic Review and Meta-Analysis.","authors":"Yueyang Zhou,Na Li,Jiahui Luo,Yuqing Chen,Yuelun Zhang,Min Dai,Hongda Chen","doi":"10.14309/ajg.0000000000003107","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003107","url":null,"abstract":"BACKGROUND AND AIMSThe evidence on the cumulative participation and yield in multiple rounds of colorectal cancer (CRC) screening based on fecal immunochemical test is sparse. We aimed to assess the trends in participation and detection for advanced colorectal neoplasm under different screening intervals in multi-round FIT-based CRC screening by synthesizing the current available evidence.METHODSPubMed, Embase, and Cochrane were retrieved from January 1, 2002 to April 16, 2024 for potential eligible studies and then we synthesized participation and advanced colorectal neoplasm detection rates for each screening round, along with their respective 95% confidence intervals.RESULTS19 studies involving a total of 2,296,071 individuals were included. As screening rounds increased, participation exhibited a gradual consistent increase, reaching 78.45% and 74.97% for annual and biennial screening strategies. For annual screening, the cumulative detection rates for 3 rounds were 1.38% (95% CI: 1.18-1.63%), 1.95% (95% CI: 1.72-2.21%), and 2.50% (95% CI: 2.29-2.72%), respectively. For biennial screening, the cumulative detection rates for 4 rounds were 2.22% (95% CI: 1.22-3.22%), 3.44% (95% CI: 2.06-4.82%), 4.26% (95% CI: 2.70-5.83%), and 5.10% (95% CI: 3.28-7.29%), respectively. Notably, the per-round detection rate of advanced colorectal neoplasms declined yet as the screening progressed.CONCLUSIONIn population-based CRC screening programs, the participation exhibited a slow upward trend for both screening strategies, but the incremental benefits in CRC detection gradually diminished. Tailored strategies, such as extending intervals for individuals with multiple negative FIT results, might optimize effectiveness and cost-efficiency in population-based CRC screening.","PeriodicalId":520099,"journal":{"name":"The American Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142328831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-27DOI: 10.14309/ajg.0000000000003106
Cary C Cotton,Mousumi Biswas,Evan S Dellon
BACKGROUNDWe aimed to estimate health state utility in eosinophilic esophagitis (EoE) by histologic activity and assess association with disease parameters.METHODSIn this cross-sectional study, we measured health state utility by time trade-off and assessed symptoms with the EoE Symptom Activity Index (EEsAI).RESULTSIn 51 adults with EoE, mean utility was 0.91 (95% CI 0.86, 0.95). Utility was numerically worse in patients with dilation or a smaller stricture diameter. With each ten-point improvement in EEsAI, utility increased by 0.03 (95% CI 0.01, 0.05).DISCUSSIONEoE is associated with reduced health state utility, with symptoms most strongly predicting valuation.
背景我们的目的是通过组织学活动来估算嗜酸性粒细胞食管炎（EoE）患者的健康状态效用，并评估其与疾病参数的关系。结果在 51 名成人 EoE 患者中，平均效用为 0.91（95% CI 0.86，0.95）。扩张或狭窄直径较小的患者效用较差。EEsAI 每提高 10 分，效用就会提高 0.03 (95% CI 0.01, 0.05)。
{"title":"Health state utility is substantially reduced with an increasing burden of patient-reported symptoms in eosinophilic esophagitis.","authors":"Cary C Cotton,Mousumi Biswas,Evan S Dellon","doi":"10.14309/ajg.0000000000003106","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003106","url":null,"abstract":"BACKGROUNDWe aimed to estimate health state utility in eosinophilic esophagitis (EoE) by histologic activity and assess association with disease parameters.METHODSIn this cross-sectional study, we measured health state utility by time trade-off and assessed symptoms with the EoE Symptom Activity Index (EEsAI).RESULTSIn 51 adults with EoE, mean utility was 0.91 (95% CI 0.86, 0.95). Utility was numerically worse in patients with dilation or a smaller stricture diameter. With each ten-point improvement in EEsAI, utility increased by 0.03 (95% CI 0.01, 0.05).DISCUSSIONEoE is associated with reduced health state utility, with symptoms most strongly predicting valuation.","PeriodicalId":520099,"journal":{"name":"The American Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142328828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-27DOI: 10.14309/ajg.0000000000003053
Ching-Pin Lin,Poi Kuo,James Cheng-Chung Wei
{"title":"Addressing Additional Limitations in the Study on Small Intestine Cancer Risk in Patients With Inflammatory Bowel Disease.","authors":"Ching-Pin Lin,Poi Kuo,James Cheng-Chung Wei","doi":"10.14309/ajg.0000000000003053","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003053","url":null,"abstract":"","PeriodicalId":520099,"journal":{"name":"The American Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142328829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-26DOI: 10.14309/ajg.0000000000003071
Liqi Li
{"title":"Small Bowel Microbiome Profiles in Overweight and Obese Humans.","authors":"Liqi Li","doi":"10.14309/ajg.0000000000003071","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003071","url":null,"abstract":"","PeriodicalId":520099,"journal":{"name":"The American Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-26DOI: 10.14309/ajg.0000000000003063
Mohammed El-Dallal,Rajan Lamichhane,Ahmed Sherif,Wesam Frandah
{"title":"Request for Clarification on Sample Size Calculation and Statistical Analysis.","authors":"Mohammed El-Dallal,Rajan Lamichhane,Ahmed Sherif,Wesam Frandah","doi":"10.14309/ajg.0000000000003063","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003063","url":null,"abstract":"","PeriodicalId":520099,"journal":{"name":"The American Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-25DOI: 10.14309/ajg.0000000000003105
Arantzazu Izagirre,Cristina Sarasqueta,Joel Flores-Arriaga,María C Aso,María Pérez,Jan Tack,I-Hsuan Huang,Ami D Sperber,Olafur S Palsson,Shrikant I Bangdiwala,Mauro D'Amato,Ángel Lanas,Beatriz Lobo,Carmen Alonso-Cotoner,Javier Santos,Luis Bujanda
BACKGROUND AIMSCyclic vomiting syndrome (CVS) is a disorder of gut-brain interaction (DGBI) of unknown origin. This study aimed to evaluate the global prevalence of this disorder and its associated factors.METHODSData were collected from nationwide Internet surveys in 26 countries, with subjects evenly distributed by age, sex and country. The survey included the Rome IV questionnaire as well as an extensive supplemental questionnaire to evaluate additional factors.RESULTS54,127 participants completed the questionnaire (51% male, mean age 44.3 years). The pooled prevalence of CVS was 0.3% (95% CI 0.3-0.4%; n=187), highest in Brazil (1%, 95% CI 0.6-1.5), and lowest in Japan and Germany (with no subject who fulfilled the criteria for CVS). The mean age of participants with CVS was 36.7 years (standard deviation 13.5) and it was more common in females (56.7% vs 43.5%). Factors independently associated with this syndrome were female sex (OR 1.52, 95% CI 1.13-2.03), young age (OR 2.57, 95% CI 1.34-4.94, for people between the ages of 18 and 39 years, compared to those older than 65 years), depression (OR 3.14, 95% CI 2.05-4.82, p<0.001) and anxiety (OR 1.79, 95% CI 1.15-2.78, p<0.001). Individuals with CVS had impaired quality of life (QoL) (PROMIS-10 score: physical QoL mean, 12.9 vs 15.5, p<0.001; mental QoL mean 12.3 vs 14.4, p<0.001) compared to others.CONCLUSIONSCVS is a relatively common disorder that has a negative impact on quality of life. It is important to raise awareness on this syndrome to avoid underdiagnosis and improve clinical practice.
背景 背景 背景 背景：环状呕吐综合征（CVS）是一种原因不明的肠脑交互障碍（DGBI）。本研究旨在评估这种疾病的全球患病率及其相关因素。方法数据来自 26 个国家的全国性互联网调查，受试者按年龄、性别和国家平均分配。调查包括罗马IV调查问卷以及一份广泛的补充问卷，以评估其他因素。结果54 127名参与者完成了问卷调查（51%为男性，平均年龄44.3岁）。汇总的 CVS 患病率为 0.3%（95% CI 0.3-0.4%；n=187），巴西最高（1%，95% CI 0.6-1.5），日本和德国最低（没有符合 CVS 标准的受试者）。CVS 患者的平均年龄为 36.7 岁（标准偏差为 13.5），女性更常见（56.7% 对 43.5%）。与该综合征独立相关的因素包括女性（OR 1.52，95% CI 1.13-2.03）、年轻（OR 2.57，95% CI 1.34-4.94，18 至 39 岁人群与 65 岁以上人群相比）、抑郁（OR 3.14，95% CI 2.05-4.82，p<0.001）和焦虑（OR 1.79，95% CI 1.15-2.78，p<0.001）。与其他人相比，CVS 患者的生活质量（QoL）（PROMIS-10 评分：身体 QoL 平均值为 12.9 vs 15.5，p<0.001；精神 QoL 平均值为 12.3 vs 14.4，p<0.001）受到影响。提高对该综合征的认识对于避免诊断不足和改善临床实践非常重要。
{"title":"Worldwide Prevalence and Description of Cyclic Vomiting Syndrome According to the Results of the Rome Foundation Global Epidemiology Study.","authors":"Arantzazu Izagirre,Cristina Sarasqueta,Joel Flores-Arriaga,María C Aso,María Pérez,Jan Tack,I-Hsuan Huang,Ami D Sperber,Olafur S Palsson,Shrikant I Bangdiwala,Mauro D'Amato,Ángel Lanas,Beatriz Lobo,Carmen Alonso-Cotoner,Javier Santos,Luis Bujanda","doi":"10.14309/ajg.0000000000003105","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003105","url":null,"abstract":"BACKGROUND AIMSCyclic vomiting syndrome (CVS) is a disorder of gut-brain interaction (DGBI) of unknown origin. This study aimed to evaluate the global prevalence of this disorder and its associated factors.METHODSData were collected from nationwide Internet surveys in 26 countries, with subjects evenly distributed by age, sex and country. The survey included the Rome IV questionnaire as well as an extensive supplemental questionnaire to evaluate additional factors.RESULTS54,127 participants completed the questionnaire (51% male, mean age 44.3 years). The pooled prevalence of CVS was 0.3% (95% CI 0.3-0.4%; n=187), highest in Brazil (1%, 95% CI 0.6-1.5), and lowest in Japan and Germany (with no subject who fulfilled the criteria for CVS). The mean age of participants with CVS was 36.7 years (standard deviation 13.5) and it was more common in females (56.7% vs 43.5%). Factors independently associated with this syndrome were female sex (OR 1.52, 95% CI 1.13-2.03), young age (OR 2.57, 95% CI 1.34-4.94, for people between the ages of 18 and 39 years, compared to those older than 65 years), depression (OR 3.14, 95% CI 2.05-4.82, p<0.001) and anxiety (OR 1.79, 95% CI 1.15-2.78, p<0.001). Individuals with CVS had impaired quality of life (QoL) (PROMIS-10 score: physical QoL mean, 12.9 vs 15.5, p<0.001; mental QoL mean 12.3 vs 14.4, p<0.001) compared to others.CONCLUSIONSCVS is a relatively common disorder that has a negative impact on quality of life. It is important to raise awareness on this syndrome to avoid underdiagnosis and improve clinical practice.","PeriodicalId":520099,"journal":{"name":"The American Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142320972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-19DOI: 10.14309/ajg.0000000000003085
Kelly Issokson,Dale Young Lee,Andres J Yarur,James D Lewis,David L Suskind
The concept of using diet as therapy in inflammatory bowel disease (IBD) is of interest to clinicians and patients. Once considered to play a minor role, diet is now known to affect not only disease onset but may also serve as a therapeutic tool for inducing and maintaining remission and improving surgical outcomes. Further research is needed to fully elucidate how, when, and in whom diet therapies may be best applied to improve clinical and disease outcomes. The aim of this review is to summarize current research findings and serve as a tool to help facilitate patient-clinician conversations.
{"title":"The Role of Diet in Inflammatory Bowel Disease Onset, Disease Management, and Surgical Optimization.","authors":"Kelly Issokson,Dale Young Lee,Andres J Yarur,James D Lewis,David L Suskind","doi":"10.14309/ajg.0000000000003085","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003085","url":null,"abstract":"The concept of using diet as therapy in inflammatory bowel disease (IBD) is of interest to clinicians and patients. Once considered to play a minor role, diet is now known to affect not only disease onset but may also serve as a therapeutic tool for inducing and maintaining remission and improving surgical outcomes. Further research is needed to fully elucidate how, when, and in whom diet therapies may be best applied to improve clinical and disease outcomes. The aim of this review is to summarize current research findings and serve as a tool to help facilitate patient-clinician conversations.","PeriodicalId":520099,"journal":{"name":"The American Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142273466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-19DOI: 10.14309/ajg.0000000000003084
Theodore Rokkas,Konstantinos Ekmektzoglou,Yaron Niv,David Y Graham
BACKGROUND AIMSIn the last few years numerous new P-CAB based RCTs concerning first-line regimens for H. pylori infection treatment from various countries have been published. However, no NWM exists which examines the comparative efficacy and safety of P-CAB based dual, triple and quadruple treatments and therefore, in this network meta-analysis (NWM) we examined this matter comparing efficacy and safety of these P-CAB based regimens.METHODSDatabases were searched for identification, screening, eligibility and inclusion of relevant randomized controlled trials (RCTs). Extracted data were entered into a Bayesian NWM and the ranking order for each regimen was evaluated by means of surfaces under cumulative ranking area (SUCRA) values.RESULTSTwenty-five eligible RCTs were included with 7,605 patients randomized to 6 first line regimens, i.e. PCAB-DUAL, PCAB-TRIPLE, PCAB-QUADRUPLE, PPI-DUAL, PPI-TRIPLE, and PPI- QUADRUPLE. The SUCRA values (%) for these 6 regimens were 92.7, 62.5, 33.9, 75.1, 19.4 and 16.3 respectively. The comparative effectiveness ranking showed that PCAB-DUAL regimen ranked first for efficacy and last for adverse effects and had the best profile for integrated efficacy-safety.CONCLUSIONSIn this NWM concerning the comparative efficacy and safety of P-CAB based dual, triple and quadruple regimens for first line H. pylori infection treatment, the overall results showed that PCAB based dual treatment ranked first for efficacy with the best-integrated efficacy-safety profile. This is of importance, since the dual regimens overcome the crucial issue of clarithromycin resistance. Consequently, these findings are expected to be useful in helping clinical decision-making and future guidelines.
{"title":"Comparative efficacy and safety of Potassium-Competitive Acid Blocker (P-CAB) based dual, triple and quadruple regimens for first line H. pylori infection treatment: A systematic review and network meta-analysis.","authors":"Theodore Rokkas,Konstantinos Ekmektzoglou,Yaron Niv,David Y Graham","doi":"10.14309/ajg.0000000000003084","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003084","url":null,"abstract":"BACKGROUND AIMSIn the last few years numerous new P-CAB based RCTs concerning first-line regimens for H. pylori infection treatment from various countries have been published. However, no NWM exists which examines the comparative efficacy and safety of P-CAB based dual, triple and quadruple treatments and therefore, in this network meta-analysis (NWM) we examined this matter comparing efficacy and safety of these P-CAB based regimens.METHODSDatabases were searched for identification, screening, eligibility and inclusion of relevant randomized controlled trials (RCTs). Extracted data were entered into a Bayesian NWM and the ranking order for each regimen was evaluated by means of surfaces under cumulative ranking area (SUCRA) values.RESULTSTwenty-five eligible RCTs were included with 7,605 patients randomized to 6 first line regimens, i.e. PCAB-DUAL, PCAB-TRIPLE, PCAB-QUADRUPLE, PPI-DUAL, PPI-TRIPLE, and PPI- QUADRUPLE. The SUCRA values (%) for these 6 regimens were 92.7, 62.5, 33.9, 75.1, 19.4 and 16.3 respectively. The comparative effectiveness ranking showed that PCAB-DUAL regimen ranked first for efficacy and last for adverse effects and had the best profile for integrated efficacy-safety.CONCLUSIONSIn this NWM concerning the comparative efficacy and safety of P-CAB based dual, triple and quadruple regimens for first line H. pylori infection treatment, the overall results showed that PCAB based dual treatment ranked first for efficacy with the best-integrated efficacy-safety profile. This is of importance, since the dual regimens overcome the crucial issue of clarithromycin resistance. Consequently, these findings are expected to be useful in helping clinical decision-making and future guidelines.","PeriodicalId":520099,"journal":{"name":"The American Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142273467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-12DOI: 10.14309/ajg.0000000000003047
Ashwani K Singal,Loretta Jophlin,Vijay H Shah
{"title":"Guidelines in Practice: Alcohol-Associated Liver Disease.","authors":"Ashwani K Singal,Loretta Jophlin,Vijay H Shah","doi":"10.14309/ajg.0000000000003047","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003047","url":null,"abstract":"","PeriodicalId":520099,"journal":{"name":"The American Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142175058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-21DOI: 10.14309/ajg.0000000000003044
Chang Woo Kim,Hyunjin Kim,Hyoung Rae Kim,Daeyeon David Won,Woo Jung Nam,Byung Soh Min,Tae Jeong Oh,Sungwhan An,Suk-Hwan Lee
INTRODUCTIONNoninvasive stool DNA-based methylation testing has emerged as an effective strategy for the early colorectal cancer (CRC) detection. Syndecan-2 (SDC2) methylation frequently occurs in all stages of CRC; therefore, the aim of this study was to evaluate the clinical performance of a stool DNA-based SDC2 methylation test for detecting CRC in asymptomatic or high-risk CRC populations.METHODSThis multicenter prospective study was conducted to determine the clinical performance of the SDC2 methylation test on stool DNA using real-time polymerase chain reaction. Stool samples were collected from asymptomatic individuals before colonoscopy, and the test results were independently analyzed through comparison with colonoscopic findings and pathological outcomes as reference standards.RESULTSOf the 1,124 evaluable participants, 20 had CRC, 73 had advanced adenomatous polyps (≥1.0 cm), 469 had nonadvanced adenomatous polyps (<1.0 cm), 178 had non-neoplastic polyps, and 384 had negative colonoscopy results. The stool SDC2 methylation test had a sensitivity and specificity of 95.0% and 81.5%, respectively, for detecting CRC, while the sensitivity for detecting advanced adenomatous polyps and CRC was 58.1%. The rate of adenoma detection increased with polyp size (P < 0.01), and sensitivity was not associated with CRC stage (P = 0.864).DISCUSSIONThe stool DNA-based SDC2 methylation test attained a high sensitivity for CRC detection in an asymptomatic high-risk population. Further large-scale clinical studies are required to validate the clinical utility of this test as a population-based CRC screening tool.
{"title":"A Stool DNA-Based SDC2 Methylation Test for the Early Detection of Colorectal Cancer in an Asymptomatic, High-Risk Population: A Multicenter Prospective Randomized Trial.","authors":"Chang Woo Kim,Hyunjin Kim,Hyoung Rae Kim,Daeyeon David Won,Woo Jung Nam,Byung Soh Min,Tae Jeong Oh,Sungwhan An,Suk-Hwan Lee","doi":"10.14309/ajg.0000000000003044","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003044","url":null,"abstract":"INTRODUCTIONNoninvasive stool DNA-based methylation testing has emerged as an effective strategy for the early colorectal cancer (CRC) detection. Syndecan-2 (SDC2) methylation frequently occurs in all stages of CRC; therefore, the aim of this study was to evaluate the clinical performance of a stool DNA-based SDC2 methylation test for detecting CRC in asymptomatic or high-risk CRC populations.METHODSThis multicenter prospective study was conducted to determine the clinical performance of the SDC2 methylation test on stool DNA using real-time polymerase chain reaction. Stool samples were collected from asymptomatic individuals before colonoscopy, and the test results were independently analyzed through comparison with colonoscopic findings and pathological outcomes as reference standards.RESULTSOf the 1,124 evaluable participants, 20 had CRC, 73 had advanced adenomatous polyps (≥1.0 cm), 469 had nonadvanced adenomatous polyps (<1.0 cm), 178 had non-neoplastic polyps, and 384 had negative colonoscopy results. The stool SDC2 methylation test had a sensitivity and specificity of 95.0% and 81.5%, respectively, for detecting CRC, while the sensitivity for detecting advanced adenomatous polyps and CRC was 58.1%. The rate of adenoma detection increased with polyp size (P < 0.01), and sensitivity was not associated with CRC stage (P = 0.864).DISCUSSIONThe stool DNA-based SDC2 methylation test attained a high sensitivity for CRC detection in an asymptomatic high-risk population. Further large-scale clinical studies are required to validate the clinical utility of this test as a population-based CRC screening tool.","PeriodicalId":520099,"journal":{"name":"The American Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142261423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：